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ARTICLE
Pediatric pan-central nervous system tumor
analysis of immune-cell infiltration identifies
correlates of antitumor immunity
Yura Grabovska1, Alan Mackay2, Patricia O’Hare3, Stephen Crosier1, Martina Finetti 1, Edward C. Schwalbe1,
Jessica C. Pickles 4,5, Amy R. Fairchild4,5, Aimee Avery5, Julia Cockle2, Rebecca Hill1, Janet Lindsey1,
Debbie Hicks1, Mark Kristiansen6, Jane Chalker7, John Anderson3,4, Darren Hargrave 3,4,
Thomas S. Jacques 5, Karin Straathof3,4, Simon Bailey 1, Chris Jones2, Steven C. Clifford1 &
Daniel Williamson 1✉
Immune-therapy is an attractive alternative therapeutic approach for targeting central ner-
vous system (CNS) tumors and the constituency of the Tumor Immune Microenvironment
(TIME) likely to predict patient response. Here, we describe the TIME of >6000 primarily
pediatric CNS tumors using a deconvolution approach (methylCIBERSORT). We produce and
validate a custom reference signature defining 11 non-cancer cell types to estimate relative
proportions of infiltration in a panCNS tumor cohort spanning 80 subtypes. We group
patients into three broad immune clusters associated with CNS tumor types/subtypes. In
cohorts of medulloblastomas (n= 2325), malignant rhabdoid tumors (n= 229) and pediatric
high-grade gliomas (n= 401), we show significant associations with molecular subgroups/
subtypes, mutations, and prognosis. We further identify tumor-specific immune clusters with
phenotypic characteristics relevant to immunotherapy response (i.e. Cytolytic score, PDL1
expression). Our analysis provides an indication of the potential future therapeutic and
prognostic possibilities of immuno-methylomic profiling in pediatric CNS tumor patients that
may ultimately inform approach to immune-therapy.
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Immune therapies are an attractive alternative anti-cancerstrategy alongside the conventional approaches of surgery,chemotherapy, and radiotherapy that may be particularly well
suited to targeting diffuse infiltratively growing tumors. The field
of cancer immunotherapy has grown expansively in recent years
to include the therapeutic use of cancer vaccinations, chimeric
antigen receptor T-cell therapy, and agents that block immune
checkpoint receptors and/or ligand interactions such as CTLA-4
and PD-1. Each can provoke a significant antitumor response in
patients within varied tumor types1–7. However, for each patient
who derives clinical benefit from a particular immunotherapeutic
agent, there are many whom do not8. The composition of the
tumor immune microenvironment (TIME) is a critical determi-
nant of tumor–immune interactions and can direct response to
treatment9. Therefore, to take full advantage of the potential of
immunotherapy—or combinations with targeted agents—treat-
ment approaches need to be tailored to the specific TIME.
Detailed studies of the TIME are being conducted to predict
response to immunotherapy and uncover mechanisms of treat-
ment resistance. Although anti-PD-1 antibodies nivolumab and
pembrolizumab, and an anti-CTLA-4 antibody Ipilimumab are
Food and Drug Administration approved and can produce dur-
able responses in patients with metastatic melanoma10–12, non-
small cell lung cancer13, and renal cell carcinoma14, the majority
of patients do not respond. Comparative studies between
responders and non-responders indicate that multiple factors,
including pre-existing T-cell infiltration, checkpoint molecule
expression within the tumor, and mutational burden with con-
sequent production of neoantigens correlate with response to
immune therapy. For instance, colorectal cancer of the molecular
subtype CMS1 are characterized by DNA mismatch-repair
defects, microsatellite instability, and hypermutation with
accompanying infiltration of CD8+ T-cells15 and expression of
immune checkpoint proteins CTLA-4, PD-1, PDL1, and IDO-
116–18. CMS1 patients show significant responses to anti-PD-1
therapies19.
Tumors are frequently described as being immunologically
“hot” or “cold” with a presumed implication for the effectiveness
of particular tumor immune therapies. “Hot” tumor TIMEs are
broadly characterized by high expression of the PD-1 ligand
(PDL1) and by infiltration of cytotoxic lymphocytes (CTLs)
expressing PD-1. “Cold” tumors being relatively sparsely infil-
trated with CTLs, at least within the tumor core8. Childhood
brain tumors are thought to be relatively immunologically “cold”
due to paucity of mutations (i.e., generally lacking neoantigens20).
To date, quite limited information on TIME in childhood brain
tumors has been published and in piecemeal manner. In adult
brain tumors, several immune cell types have identified roles in,
and associations with, tumor development. For instance, tumor-
associated macrophages are believed to make up a large pro-
portion of immune cells in gliomas21 and to be generally
pro-tumorigenic and associated with a higher tumor grade22,23.
Furthermore, the number of neutrophils appears to have prog-
nostic value24,25 and immuno-suppressive regulatory T-cells
(Treg) are significantly increased in patients with glioma as a
proportion of the peripheral CD4+ cell pool; they also account
for a substantial proportion of the TIME26,27. Simple extrapola-
tion from adult brain tumors is unlikely to be informative given
the underlying differences in tumor biology.
A number of methods exist to characterize and quantify TIME
directly, e.g., immunohistochemistry (IHC), fluorescence-assisted
cytometry (FACS), cytometry by time-of-flight (Cy-TOF), and
single-cell RNA sequencing (RNA-seq). These may be costly,
laborious, and/or difficult to multiplex. Indirect techniques have
been developed to estimate TIME in silico by deconvoluting
complex mixtures of cell types from profiles of bulk populations
using pure populations of cell types as a reference28–30. CIBER-
SORT is a notable algorithm that uses support vector regression
modeling to deconvolute cell types and has been applied to several
cancer datasets28. Central nervous system (CNS) tumors have
been extensively DNA methylation profiled using arrays, most
prominently by Capper et al.31 who published a cohort of 3764
CNS tumors (including 1403 patients < 18 years old) representing
80 tumor DNA methylation types and subtypes closely related to
World Health Organization (WHO) histopathological entities. We
and others have published further large series of some of the major
pediatric CNS types, i.e., medulloblastoma (MB)32–35, atypical
teratoid/rhabdoid tumors (ATRT)36,37, and pediatric high-grade
gliomas (pHGG)38,39 with extensive clinical annotation and par-
allel multiomic data (RNA-seq, copy-number profiles, exome/
whole-genome sequencing). Here we use methylCIBERSORT—a
recent adaptation of the CIBERSORT algorithm, which uses
genome-wide DNA methylation data40—to characterize the TIME
of >6000 CNS tumors, assessing variation and the relationship
with clinico-pathology or outcome. 850K methylation arrays are
currently employed in several countries as part of a standard
diagnostic workup. We show that the ability to characterize
multiple cell types in a single experiment and generate immune
infiltrate estimates from the same data generates significant
added value.
Results
Generation of a signature matrix for cellular deconvolution.
We first constructed a signature matrix from reference DNA
methylation profiles of pure flow-sorted populations of cells. This
signature matrix represents a set of differentially methylated
CpGs selected and weighted to reflect specificity for a given cell
type and is used as the basis of cell deconvolution by methylCI-
BERSORT. Our final signature matrix consisted of 2215 differ-
entially methylated CpGs distinguishing between 12 broad cell
types: Tregs, CD4+ T-cells (CD4T), CD8+ T-cells (CD8T), B-
cells (B-cell), natural killer (NK) cells, eosinophils, neutrophils,
monocytes, endothelial cells, glial cells, neurons, and cancer.
Where cancer represents relevant cancer cell line profiles from
multiple tumor types (see Supplementary Table 1), we verified the
following: (i) that specific differentially methylated CpGs were
captured for each cell type, (ii) the absence of batch effects fol-
lowing processing; and (iii) the CpGs selected were not con-
founded by being specific to any particular CNS cancer type
(Fig. 1a, b and Supplementary Fig. 1).
We benchmarked our new signature matrix using publicly
available methylation profiles of peripheral blood mononuclear
cells (PBMCs) with known cell composition as determined by
flow cytometry or constituted from mixtures of reference DNAs
of known proportions. We found a significant level of correlation
between our methylCIBERSORT estimates and the flow cyto-
metry measurements and known DNA mixtures (ρ= 0.84, p <
0.001, n= 36 and ρ= 0.91, p < 0.001, n= 72, respectively, Fig. 1c).
We also tested 100 synthetic mixtures for each cell type generated
in silico using methylation profiles of random pure cell
populations mixed 1 : 4 with a mixture of cancer cell line profiles
(Fig. 1d). Again, there was a highly significant correlation
between estimated and actual cell composition (ρ= 0.98, p <
0.001, n= 1100). Finally, we measured the extent of immune cell
tumor infiltration using IHC (CD20, CD8) in a subset of our
tumor samples (n= 30). We were able to validate our
methylCIBERSORT estimates of B-cell and CD8+ T-cells against
our IHC-based estimates (Fig. 1e, f).
PanCNS tumors show significant differences in TIME by type.
We next applied methylCIBERSORT to a set of 3764 panCNS
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tumor methylation profiles (plus an additional 141 control/
hematopoietic samples, see Supplementary Table 4) published by
Capper et al.31. This reference set is the training resource of the
Molecular Neuro-Pathology 2.0 classifier and represents 80
methylation tumor types/subtypes closely related to WHO his-
topathological entities and divided into 13 broad histological
categories. A relative proportion of the 12 cell types were esti-
mated and indicators of deconvolution performance examined.
As further validation, the relative proportion of cancer cells
estimated by methylCIBERSORT was significantly correlated with
the estimate of tumor purity provided by Capper et al.31 (based on
machine learning estimates trained on a set of known glioma
positives) (ρ= 0.71, p < 0.01, n= 3784, Supplementary Fig. 4A).
The sum of the estimated proportions of all tumor-infiltrating
lymphocytes (TILs) (i.e., Treg, CD4T, CD8T, and NK) correlates
significantly with the meTIL score (an independent measure of T-
lymphocyte infiltration based upon methylation status of 5 CpGs)
defined by Jeschke et al.41 (ρ= 0.29, p < 0.001, n= 3764,
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Supplementary Fig. 4B). As expected, control samples having a
known inflammatory or reactive tumor microenvironment were
associated with a large increase in the estimated median propor-
tion of neutrophils (86% vs. 0%, W= 0, p < 0.001) and monocytes
(50% vs. 17%, W= 17, p < 0.001), respectively, compared to the
average of other CNS control tissues (Supplementary Fig. 4C).
Calculating the median estimated relative proportions of non-
cancer cell types showed that on average across all CNS tumor
types the largest fractions of non-cancer cells proportionally were
Tregs (20% of all non-cancer cells) and monocytes (20%)
followed by B-cells (16%), CD8T (14%), eosinophils (12%), NK
cells (12%), CD4T (9%), and neutrophils (8%). Relatively modest
proportions of neuronal (3%), endothelial cells (2%), and glia
(1%) were estimated.
Individual tumor types/subtypes varied significantly in the
relative proportions of infiltrating cell types; each cell type was
significantly non-randomly distributed with respect to tumor
type/subtype (as calculated by Kruskal–Wallis (KW) one-way
analysis of variance, each p < 0.001, see Supplementary Data 1)
(Fig. 2a, b). Post hoc testing (Dunn’s test) reveals the relative
number of TILs and indeed the total amount of infiltrating cells
was significantly less in high-grade tumor types such as
embryonal tumors (i.e., MB, ATRT, and Embryonal tumours
with multilayered rosettes) than in low-grade gliomas (LGGs)
(p < 0.001). Examining the median relative proportions of the 11
non-cancer cell types across CNS tumors, those with the greatest
variance are monocytes, Tregs, and CD8T. Notably, LGG
subtypes have a proportionally greater number of monocytes,
making up an estimated 35% of all infiltrating cells (Supplemen-
tary Fig. 4D) compared to 13% in embryonal tumors. CD8T, e.g.,
is proportionally greater in MBGrp3 and MBSHHCHLD, making up
an estimated 48% and 40% of all infiltrating cells, respectively,
compared to 6% in LGG. Tregs are relatively greater proportion-
ally in the Sellar tumors (specifically pituitary adenomas)
constituting an estimated 36% of all infiltrating cells compared
to 14% in glioblastoma and 17% in embryonal tumors (Fig. 2b
and Supplementary Fig. 4D).
Consensus clustering of immune cell estimates identifies an
optimal three immune clusters we refer to as panCNSIC1-3.
Members of panCNSIC1 have a relatively high proportion of Tregs
and a relative lack of CD8T cells. panCNSIC2 have a relatively high
proportion of CD8T and low proportions of CD4T/Tregs and NK
cells. panCNSIC3 has a relatively high proportion of monocytes
and relative lack of CD8T (Supplementary Fig. 4E). Membership
of an immune cluster was related to but by no means exclusively
dictated by tumor type. Although immune cluster is significantly
non-random with respect to tumor subgroup/subtype (χ2=3303,
p < 0.001), most tumor subgroups cut across multiple immune
clusters to some extent (Supplementary Fig. 5A).
The significance of association with available clinico-pathological
characteristics (WHO grade, disease stage, i.e., metastases/relapse/
diagnosis, age category, i.e., <3 years/3–16 years/>16 years, tumor
location, gender) was assessed and the proportion of immune cell
types was significantly associated with each of the clinico-
pathological characteristics with the exception of gender (see
Supplementary Data 1). The strongest association was with WHO
grade for which the average infiltration of certain immune cell types
(eosinophils, CD4T, B-cell, Treg, NK, monocytes, and TILs)
decreases proportionally with increasing WHO Grade (I–IV)
(Fig. 2c and Supplementary Fig. 4E). Immune cluster membership
is significantly associated with WHO grade (χ2= 1249.3, p < 0.01).
Eighty-seven percent (509/587) of all WHO Grade I tumors belong
to panCNSIC3 and panCNSIC2 consists of 86% (492/571) Grade IV
tumors (Fig. 2d). Such associations are unsurprising given the
strong interdependence of clinico-pathological factors with tumor
subtype. However, a regression analysis using only tumor types for
which grade, age category, and tumor location were variable showed
a number of clinico-pathological associations significant indepen-
dently of tumor subgroup (see Supplementary Data 1). B-cells,
CD4T, eosinophils, and Tregs were each significantly negatively
associated with tumor stage (each p < 0.01) independently of the
subgroup. Monocytes were also significantly positively associated
with spinal location independent of the subgroup. In summary, this
analysis reveals the existence of at least three distinct TIME classes
across CNS tumors strongly related to but not exclusively dictated
by tumor subgroup and grade.
Medulloblastoma TIME is related to molecular subtype. We
next sought to characterize a more refined TIME in a single
tumor type. By applying methylCIBERSORT to a set of 2325 MB
methylation profiles, published by ourselves and others32–35, for
which more detailed clinico-pathological and parallel multiomics
data were available. Each of these studies elaborated upon the
four classic subgroups of MB (MBWNT, MBSHH, MBGrp3, and
MBGrp4)42 to describe further derivative subtypes including high-
risk or low-risk subtypes of MBGrp3/Grp4. The most abundantly
estimated infiltrated non-cancer cell types on average across all
MB subgroups were CD8T (27% of all non-cancer cells), B-cells
(16%), and eosinophils (15%). The proportion of each cell type
was significantly different with respect to the four classic sub-
groups (all p < 0.001, see Supplementary Data 1) and post hoc
testing shows significantly greater CD8T in MBGrp3 vs. MBGrp4
(7.3-fold, p < 0.001), greater NK in MBGrp4 vs. other subgroups
(9.7-fold, all comparisons p < 0.001), and greater B-cells in
MBSHH vs. other subgroups (3-fold, all comparisons p < 0.001)
(Fig. 3a, b).
We recently published a meta-analysis describing a further
refinement of the MBGrp3/Grp4 subgroups into eight subtypes
Fig. 1 Generating and benchmarking the signature matrix. a Heatmap of β-values for CpGs (rows) and samples (columns) used in the methylCIBERSORT
signature matrix. Columns/rows are ordered by unsupervised hierarchical clustering which independently resolves reference cell type. b t-SNE plot showing
methylation profiles of the pure reference cell types. c Barplot showing the methylCIBERSORT estimates of immune-cell-type proportions (MC) vs. known
flow-validated proportions in six control PBMC cell mixtures (FV) or artificial mixtures generated from combined known proportions of isolated immune cell
types (MIX). d Scatterplot showing a significant correlation (Pearson, ρ= 0.98, p < 0.001, n= 1100) between known input and methylCIBERSORT estimates
of randomly simulated cell mixtures created in silico to contain 75% cancer and known proportions of input cell types. e Boxplots showing results of
immunohistochemical (IHC) staining of medulloblastoma (MB) and malignant rhabdoid tumor (MRT) tissue sections with antibodies for CD20 and CD8;
n= 30 biologically independent samples. % positive cells are shown by “High” and “Low” categories. “High” represents five samples (for which tissue
sections were available) with the highest methylCIBERSORT estimate for either B-cells or CD8+ T-cell infiltration samples. “Low” represents five samples for
which a methylCIBERSORT estimation of B-cells or CD8+ T-cell infiltration was 0 or negligible. Discontinuous axes are used where needed to represent
outliers. Data represents the % positive cells from a minimum of 15,000 cells assessed per sample (median cells examined= 826,375). Box represents
interquartile range, center line represents median, whiskers represent range of minima and maxima excluding outliers, which are represented as points. f
Images of IHC staining showing examples from the aforementioned “High” and “Low” categories. Scale bar represents 100 μM.
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I–VIII35. These subtypes are also associated with differences in
estimated levels of each cell type with the exception of monocytes
(each p < 0.002, see Supplementary Data 1). Post hoc analysis
shows the most significant differences to be CD8T (greater in
subtype II), Tregs (less in subtype II), NK (greater in subtype
VIII), and B-cells (less in subtype III) (all comparisons p < 0.01)
(Fig. 3a, b). Significant differences were apparent between MBSHH
subtypes. Both the infant SHH subtype (described by Schwalbe
et al.32) and the SHH γ-subtype (described by Cavalli et al.33)
show significantly greater proportions of B-cells than other
MBSHH subtypes (2.6- and 2.5-fold, respectively, both p < 0.001)
(Fig. 3a, b).
Consensus clustering of MB immune cell estimates identifies
an optimal four immune clusters referred to here as MBIC1-4,
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which cut across each of the MB subgroups/subtypes (Supple-
mentary Fig. 6A). These amount to further refinements of the
immune clusters defined in the panCNS tumor analysis with
MBIC1/MBIC4 overlapping primarily with panCNSIC2 and MBIC2/
MBIC3 overlapping primarily with panCNSIC1 (Supplementary
Fig. 5B). MBIC1 constitutes 7% (167/2325) of all MB and is
characterized by relatively high proportions of B-cells and CD8T,
and a disproportionately high number of MBSHH patients; 83% of
MBIC1 are also MBSHH (χ2= 425.59, p < 0.001). MBIC2 constitutes
7% (162/2325) of all MB and is characterized by relatively high
proportions of Treg, eosinophils, and NK, and low proportions of
CD8T. MBIC3 constitutes 42% (981/2325) of all MB, has relatively
low proportions of CD8T, relatively moderate levels of all other
infiltrating immune types, and a disproportionately high propor-
tion of MBGrp3/Grp4 (78% of MBIC3). MBIC4 constitutes 44%
(1015/2325) of all MB and is characterized by a relatively high
proportion of CD8T cells and relatively low–moderate levels of
other infiltrating immune cell types (Supplementary Fig. 6A).
Further associations between infiltrating cell estimations and
clinico-pathological variables (within the four classic subgroups)
were examined includingthe following: MYC/MYCN amplifica-
tion, TP53 mutation, and metastatic stage (see Supplementary
Data 1). MYC amplification in MBGrp3 was associated with a
significantly higher proportion of TILs, CD8T, and B-cells (KW
= 8.7, 16.7, 18.9, respectively, each p < 0.01, n= 408), and a lower
infiltration of Tregs (KW= 11, p= 0.012, n= 408) (Supplemen-
tary Fig. 6B).
Estimated immune cell infiltration was examined for association
with survival in each subtype (excluding MBWNT). Membership of
MBIC2 was associated with poorer overall survival (OS) in MBGrp4
(log-rank p= 0.0079, n= 399) (Fig. 3c). Cox regression shows
several individual cell types are significantly associated with
outcome (see Supplementary Data 1). In some instances, immune
cell estimates provide prognostic information independent of
previously established survival associated methylation subtypes32.
For instance, a greater than median proportion of monocytes
in MBGrp4 is associated with a poor prognosis (OS: hazard ratio
(HR)= 1.7, CI95%upper= 2.5, CI95%lower= 1.2, p= 0.006, n=
399; progression-free survival (PFS): HR= 1.9, CI95%upper= 3.7,
CI95%lower= 1.0, p= 0.039, n= 133). Multivariate analysis shows
that this association is significantly prognostic, independent of the
MBGrp4 high-risk/low-risk subgrouping of Schwalbe et al.32 (OS:
HR= 2.2, CI95%upper= 4.5, CI95%lower= 1.1, p= 0.023, n= 135;
PFS: HR= 2.0, CI95%upper= 3.8, CI95%lower= 1.1, p= 0.032,
n= 133) (Supplementary Fig. 6C). For infant MBSHH, a greater
than median proportion of Tregs was significantly associated with
a poor PFS (OS: HR= 3.3, CI95%upper= 8.9, CI95%lower= 1.2,
p= 0.021, n= 64; PFS: HR= 2.7, CI95%upper= 6.4, CI95%lower=
1.1, p= 0.029, n= 59) (Supplementary Fig. 6D). Likewise, the
proportion of Tregs distinguishes two groups within the previously
described MBGrp3 low-risk subtype32 with significantly different
survival (log-rank p < 0.001, 5yrEFS 88% vs. 52%) (Fig. 3d). This
demonstrates that immune infiltration estimates are able to add
additional prognostic information not readily available from
previous methylation-based analysis.
In order to independently validate our findings, we analyzed, a
subset of MB samples for which we possessed both methylation
and RNA-seq data. We calculated the expression-based metric
“Cytolytic score” (CYT= the mean expression of GZMA and
PRF1) as described by Rooney et al.43 and showed that this was
significantly correlated with methylCIBERSORT estimates of
TILs (ρ= 0.18, p= 0.015, n= 185) and differed significantly by
immune cluster (F= 4.1, p= 0.008, n= 185) being greatest in
MBIC1 and poorest in MBIC3 (Supplementary Fig. 6E). Expression
of immune checkpoint genes PDL1 and CD276 were also
significantly different with respect to immune clusters (both
p < 0.01); MBIC1 in particular showed high expression of PDL1
and low expression of CD276. We used ssGSEA analysis and gene
sets, which define two of the largest and most variable infiltrating
cell types B-cell and CD8T, to create a per-patient metagene
score, which summarizes the strength of the relevant expression
signature. This was performed in both our RNA-seq cohort and a
matched Affymetrix expression array cohort (n= 763) each was
significantly correlated with their equivalent methylCIBERSORT
estimates (each p < 0.01). Matching enrichment in CD8T
expression signatures were found in MBSHH, MBWNT, and
MBGrp3/4 subtypes and increases in B-cell expression signatures
within MBSHH and MBGroup3/4 II supports the methylCIBER-
SORT estimates (Supplementary Fig. 7A, B). Likewise, the relative
lack of CD8T in MBIC3 and B-cell enrichment in MBIC1 is
mirrored by the expression signature analysis (Supplementary
Fig. 7C, D).
MRT TIME is associated with subtype, location, and prognosis.
We next ran our methylCIBERSORT on a set of 229 malignant
rhabdoid tumor (MRT) methylation profiles from a previously
published study36 and supplemented with 79 previously unpub-
lished profiles. The MRT cohort was made up of 192 ATRT
samples and 37 extra-cranial rhabdoid tumors (ECRT). MRT are
on average infiltrated predominantly by Tregs (19% of non-cancer
cells), monocytes (18%), B-cells (15%), and CD8T (13%) (Fig. 4a,
b). Taking the three previously described molecular subgroups of
ATRT (ATRT-TYR, ATRT-SHH, and ATRT-MYC36) and ECRT,
the distribution of each estimated immune cell type is significantly
different with respect to ATRT subgroup (all p < 0.05) (Fig. 4a, b
and Supplementary Fig. 8B). Post hoc testing shows the most
significant are NK, Treg, B-cells (each greater in ATRT-TYR), and
CD8T (significantly greater in ATRT-MYC and ATRT-SHH)
(Fig. 4a, b and Supplementary Fig. 8B). Surprisingly, no immune
cell types were found to be significantly different overall between
ATRT (all subtypes) and ECRT (Fig. 4a).
Consensus clustering of MRT immune cell infiltration
estimates identifies four robust immune subgroups, which cut
Fig. 2 Deconvolution analysis of panCNS tumor immune infiltration. a Barplots of the estimated median infiltration of specific cell types as a proportion of
all non-cancer cell types (range scaled from 0 to 1) in 3763 CNS tumor samples from the Capper et al.31 panCNS tumor cohort. Data shown by tumor type/
subtype highlighting the range and variation of immune cell infiltration in different CNS tumor types. b t-SNE plot representing the methylation profiles of
the panCNS cohort. The colors of dots and a text label marking tumor type/subtype in the central panel map to the tumor type are as per Capper et al.31
(for full key see Supplementary Table 4). Background shading represents the 2D spatial density estimation of the amount of tumor-infiltrating lymphocytes
(TILs); red shading equals relatively greater than average infiltration and blue shading equals less than average. Exploded side panels represent enlarged
areas of interest wherein both dot color and background shading represent the relative amount of the particular immune cell infiltration denoted. Red color
denotes relatively greater than average infiltration and blue color denotes less than average. c Boxplot showing a negative association between proportion
of estimated cell types and WHO grade; n= 2315 biologically independent samples. Box represents interquartile range, center line represents median, and
whiskers represent range of minima and maxima excluding outliers that are represented as points. d Barchart showing differences in frequency of patients
of different WHO grade by immune cluster; n= 2315 biologically independent samples.
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across the tumor subgroups and are named MRTIC1-4. These
amount to further refinements of the immune clusters defined in
the panCNS tumor analysis with MRTIC2 overlapping primarily
with panCNSIC1 and MRTIC4 overlapping primarily with
panCNSIC2 (Supplementary Fig. 5C). MRTIC1 and MRTIC3
constitute minor clusters, only 2% (4/229) and 6% (14/229) of
all MRT, and have relatively high proportion of neutrophils and
monocytes, respectively. Both clusters contain a disproportionate
number of ECRT and ATRT-TYR (χ2= 48.218, p < 0.001)
(Supplementary Fig. 8A). MRTIC4 constitutes 32% (74/229) of
all MRT and is characterized by a relatively high proportion of
CD8T and relatively low infiltration of other immune cell types.
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MRTIC2 constitutes 60% (137/229) of all MRT and is character-
ized by a relative lack of CD8T and relatively moderate infil-
tration of other immune cell types; 83% (59/71) of ATRT-TYR
are of this type.
Examining the association with outcome in ATRT, we found a
greater than median level of B-cells was associated with a
significantly improved OS (log-rank, p= 0.048, n= 35) (Fig. 4c).
In ECRT, a greater than median level of CD8T was associated
with a significantly poorer OS (log-rank p= 0.012, n= 24)
(Fig. 4d). It should be noted that molecular subgroup alone was
non-significant with respect to OS in both ATRT and ECRT.
No significant differences in immune infiltration are seen with
respect to age category (<2 vs. >2 years), the presence of metastases
at diagnosis, and type of SMARCB1 mutation (Supplementary
Data 1). The only significant clinico-pathological association is a
lower proportion of monocytes and a higher proportion of NK
cells in infratentorial compared to supratentorial ATRT (W=
1469.5 and W= 2726.5, respectively, both p < 0.001) (Supplemen-
tary Fig. 8C, D).
To validate our methylCIBERSORT results, a CYT score was
again calculated in samples for which parallel RNA-seq data were
available. This was significantly correlated with methylCIBER-
SORT estimates of TILs in MRT (p < 0.01, n= 28) (Supplemen-
tary Fig. 9A). We also used mixcr44 analysis to identify non-
germline (i.e., definitively rearranged and therefore originating
from T-cells or B-cells) BCR and TCR reads within the RNA-seq
data and thus CDR3 clonotypes. The total normalized TCR and
BCR read counts correlated significantly with the methylCIBER-
SORT estimates of T-lymphocytes and B-cells, respectively (each
p < 0.05, Supplementary Fig. 9B, C). MRTIC2 had a 1.8-fold lower
mean CYT score and 1.7-fold greater mean PDL1 expression than
that of MRTIC4 (Supplementary Fig. 9D). Using the same ssGSEA
approach as for MB shows enrichment of CD8T and B-cell
expression signatures matching methylCIBERSORT estimates
according to subtype (Supplementary Fig. 9E, F). Taken as a
whole, this underlines the significant relationships between
subgroup, prognosis, and immune cell infiltration in MRT.
TIME is associated with subtype, histone mutation, and
prognosis in HGG. Finally, we analyzed a cohort of 401 primarily
pHGG samples published by Mackay et al.38,39. pHGG were, on
average, infiltrated predominantly by monocytes (26% of non-
cancer cells), Tregs (15%), and eosinophils (13%) (Fig. 5a). CD8T
infiltration in pHGG was generally less than MB and MRT. Sev-
eral cell types varied significantly with respect to tumor subgroup
as defined by MacKay et al.38, i.e., WT-A, WT-B, WT-C, IDH,
GBM G34, and GBM K27. These include monocytes, CD8T, TILs,
and eosinophils (each p < 0.001) (see Supplementary Data 1 and
Fig. 5a, b). Post hoc testing shows significantly greater monocytes
in WT-A vs. other subgroups (2.9-fold, all comparisons p < 0.001),
significantly greater CD8T in GBM with G34 mutations (1.7-fold,
all comparisons p < 0.05), and significantly less eosinophils in
GBM with G34 mutations (2.3-fold less, all comparisons p <
0.001). Furthermore, the number of TILs and indeed the overall
level of immune cell infiltration is significantly higher in the WT-
A subgroup (1.6-fold greater and 1.9-fold greater, respectively, all
comparisons p < 0.01) and significantly lower in GBM G34 than
other pHGGs (1.8-fold and 2.0-fold, respectively, all comparisons
p < 0.01). The WT-A subgroup generally contains pHGG, other-
wise referred to as PXA or LGG-like; they are also enriched for
mitogen-activated protein kinase (MAPK) mutations (genes NF1,
FGFR1, NTRK2, BRAF, see Supplementary Data 1).
Consensus clustering of pHGG immune cell estimates identifies
an optimal three immune clusters referred to here as pHGGIC1-3,
which cut across each of the pHGG subtypes (Supplementary
Fig. 10A). pHGGIC3 overlaps primarily with panCNSIC1/panCN-
SIC2 and pHGGIC2 overlaps with panCNSIC3 (Supplementary
Fig. 5C). pHGGIC1 constitutes 31% (126/401) of all pHGG and is
characterized by high proportions of Tregs, eosinophils, NK, and
CD4T. pHGGIC2 constitutes 17% (71/401) of all pHGG and is
characterized by high proportions of monocytes and a dispropor-
tionately high frequency of WT-A subtypes; 77% (55/73) of all
pHGGIC2 are also WT-A. pHGGIC3 constitutes 51% (204/401) of
all pHGG and tumors show intermittently moderate levels of
CD8T and relatively low levels of other infiltrating immune cell
types. Eighty-seven percent (43/49) of all GBM G34 belong to this
cluster (Supplementary Fig. 10A, B). As pHGG generally had
higher monocytic infiltration than MB/MRT, we took the
opportunity to consider what proportion of the monocyte
signature might be attributed to microglia as opposed to infiltration
from peripheral blood. In the absence of an appropriate
methylation signature, we adapted a set of expression markers
from Haage et al.45, which can distinguish peripheral monocytes
from microglia. Where we possessed parallel expression profiles,
we were able to estimate that a median 52% (range of 28–77%) of
the monocyte infiltration could be attributed to microglia. This is
consistent with proportion estimated by FACS in adult HGG as
reported by Gabrusiewicz et al.46 (Supplementary Fig. 11).
Examining the association of cell infiltration with survival within
each of the pHGG subgroups using Cox regression reveals the
following significant associations (see Supplementary Data 1).
Lower than median concentrations of B-cell and CD8T in WT-A
patients are associated with a poor OS (HR= 4.3 CI95%upper= 9.0,
CI95%lower= 2.0, p < 0.001, n= 80 and HR= 4.3, CI95%upper=
18.2, CI95%lower= 1.1, p= 0.047, n= 80, respectively). Higher
than median concentrations of CD4T and NK in GBM G34
patients is associated with a poor OS (HR= 2.4, CI95%upper= 5.3,
CI95%lower= 1.09, p= 0.028, n= 42 and HR= 3.0, CI95%upper=
7.3, CI95%lower= 1.2, p= 0.016, n= 42, respectively) (Fig. 5c and
Supplementary Fig. 10C, D).
Clinico-pathological/biological features examined for associa-
tion with estimated cell types include WHO stage, gender, age <1
year or age <3 years, and the presence of BRAF and/or
other MAPK mutation. Several immune types were significantly
associated with these clinico-pathological criteria (see Supplemen-
tary Data 1). As previously noted39, the presence of MAPK
Fig. 3 Deconvolution analysis of medulloblastoma immune infiltration by subgroup. a Barplots of the estimated median infiltration of specific cell types as a
proportion of all non-cancer cell types (range scaled from 0 to 1) in 2325 medulloblastoma by subgroup (classic 4 medulloblastoma consensus subgroups42) by
SHH subtype32,33 and by 10 group consensus as per Sharma et al.35. b t-SNE plot representing the methylation profiles of 2325 medulloblastoma. The colors of
dots in the central panel map to the classic four molecular subgroups: red, SHH; blue, WNT; yellow, Grp3; green, Grp4. Text represents centroids of individual
subtypes as reported variously by Cavalli et al.33, Sharma et al.35, and Schwalbe et al.32. Background shading represents the 2D spatial density estimation of the
amount of tumor-infiltrating lymphocytes (TILs); red shading equals relatively greater than average infiltration and blue less than average. Exploded side panels
represent enlarged areas of interest wherein both dot color and background shading represent the relative amount of the particular immune cell infiltration
denoted. Red denotes relatively greater than average infiltration and blue less than average. c Kaplan–Meier plot showing significant difference in overall survival
in MBGrp4 by immune cluster; log-rank p=0.008, n= 399. d Kaplan–Meier plot showing significantly different progression-free survival (PFS) within the
MBGrp3 Schwalbe et al.32 subtypes by low (<median) or high (>median) levels of Treg infiltration; log-rank p < 0.001, n= 101.
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mutations was associated with higher immune cell infiltration,
specifically of monocytes and CD4T cells (W= 3614 and W=
3453, respectively, both p < 0.001). In addition, nine patients who
possessed a hypermutator phenotype showed a significantly higher
estimated levels of TILs (KW= 5.0, p= 0.025, n= 137). For a
subset of samples, histopathology-based estimates of lymphocyte
infiltration were available, which categorized patients as per
Rutledge et al.47. Estimates of TILs were significantly greater in
patients classified as Categories 1 (present) or 2 (abundant) than
Category 0 (absent) (F= 7.839, p < 0.01, n= 61). Again, taken as a
whole, the significant relationships between molecular subgroup,
prognosis, mutation, and immune infiltration in pHGG are clear.
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Fig. 4 Deconvolution analysis of malignant rhabdoid tumors immune infiltration. a Barplots of the estimated median infiltration of specific cell types as a
proportion of all non-cancer cell types (range scaled from 0 to 1) in 229 malignant rhabdoid tumors (MRTs) by subgroup (three molecular subgroups
originally described by Johann et al.36) and by tumor location. ATRT, atypical teratoid/rhabdoid tumor (within the CNS, i.e., intracranial); ECRT, extra-
cranial rhabdoid tumor. b t-SNE plot representing the methylation profiles of 229 MRT. The colors of dots in the central panel map to molecular subgroups
(as per Johann et al.36). Text represents centroids of individual subtypes. Background shading represents the 2D spatial density estimation of the amount
of tumor-infiltrating lymphocytes (TILs); red shading equals relatively greater than average infiltration and blue less than average. Exploded side panels
represent enlarged areas of interest wherein both dot color and background shading represent the relative amount of the particular immune cell infiltration
denoted. Red denotes relatively greater than average infiltration and blue less than average. c Kaplan–Meier plot showing significantly different overall
survival (OS) in ATRT with > or <median numbers of B-cells; log-rank, p= 0.048, n= 35. d Kaplan–Meier plot showing significantly different overall
survival (OS) in ECRT with > or <median numbers of CD8+ T-cells; log-rank, p= 0.012, n= 24.
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Discussion
Using a methylation-based deconvolution analysis, we have
described the TIME of >6000 individual (primarily pediatric)
CNS tumors. We find diversity in TIME composition across these
CNS tumors and demonstrate significant associations variously
with tumor type, subtype, stage, grade, location, mutation, and
survival. The notion of the CNS, and by association CNS tumors,
as immune privileged and inaccessible to immune cells is
increasingly outdated3; nevertheless, our analysis lends weight to
the idea of a diverse TIME across a wide range of CNS tumors.
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We establish here a base of knowledge by which future, more
focused and in-depth investigations into the TIME of particular
pediatric CNS tumor types may be directed.
The implications of our results are as follows. First, that the
nature of immune cell content is associated with—but not exclu-
sively dictated by—a particular tumor type or subtype. Second, that
at least three broad CNS TIME subgroups strongly associated with
tumor type and grade can be identified by clustering immune cell
types, and that within individual tumor types (MB, ATRT, and
pHGG) further immune subgroups may be described. Immune
subgroups cut across the conventional CNS molecular tumor
subgroups such that a patient may simultaneously belong to a
given molecular subgroup and also independently a particular
immune subgroup. Furthermore, these immune subgroups have
different immunophenotypic characteristics (different CYT scores,
expression of PDL1, etc.) and are associated with WHO Grade.
Third, that key molecular features recognized as molecular drivers,
such as MYC amplification in MB or H3.3G34 mutations in HGG,
are associated with distinct TIMEs and particular infiltrating cell
types raising the possibility that these mutations are directly
influencing the tumor microenvironment, perhaps as an adjunct to
their intrinsic oncogenic mechanism. Fourth, that by extracting
molecular information about TIME, we are able to access sig-
nificant prognostic information independent of conventional
molecular subgroups raising the possibility of their future incor-
poration into existing prognostic biomarker schemes. It should be
noted that prognostic associations with immune cell infiltration
appear to be context dependent; increased CD8T infiltration, for
instance, does not universally denote a poor outcome. The most
directly comparable experience in pHGG was the HERBY Phase II
Trial39. High CD8+ infiltration was significantly associated with
increased survival in 34 cases (of various subtypes) who received
Temezolomide/radiotherapy and Bevacizumab for which our
results in pHGG WT-A are in accordance. This is in contrast to
ECRT where the opposite association is found with survival; this is
a more unusual but not unprecedented finding, at least in other
tumor types48–50.
Our results are broadly in accordance with the small number of
recent investigations into immune infiltration in pediatric CNS
tumors. Mackay et al.39 identified a relative lack of TILs in his-
tone mutant pHGG compared to hypermutator and PXA-like
(WT-A) subgroups, and this is borne out by our analysis here.
Expression analysis of a mixed cohort of adult and pediatric
gliomas by Bockmayr et al.51 identifies four immune clusters
(including monocyte and T-cell-dominated clusters) not wholly
inconsistent with our own. They show some associations with OS;
however, these are mainly within the older (>40 years) and IDH-
mutated subgroup. Bockmayr et al.52 also analyzed expression (by
microarray) of immune markers in 763 MBs and concluded, like
us, that MBSHH tumors had larger numbers of T-cells overall than
other subgroups. In contrast to our findings, they did not identify
associations with MB survival as was the case for the study of 26
MB patients by Vermeulen et al.53.
methylCIBERSORT is a method of convenience, especially
given the prevalent use of methylation profiling within pediatric
CNS tumors. Limitations of tumor biopsies and representative
sampling notwithstanding, our analysis provides much breadth
but clearly not the depth that may be achieved by single-cell
RNA-seq analysis. Our analysis is further limited by its reliance
on pure cell populations and an assumption that the methylation
signatures of these cells are identical to their counterparts within
the tumor stroma. In other words, one cannot exclude the pos-
sibility that the tumor microenvironment could affect the
immune cell methylome with respect to some of the CpGs within
our signature matrix. It should also be noted that there is likely
“dark-matter,” i.e., immune infiltration for which our reference
population are absent or incomplete. Nevertheless, we have made
efforts to validate and benchmark our estimates. First, by accu-
rately estimating gold-standard flow-validated cell mixtures and
by simulating mixtures of cell types (Fig. 1b, c). Second, by
matching our own estimates of infiltrating lymphocytes and
tumor purity with independent estimates or alternative algo-
rithms (meTIL score), and by the use of control samples with
known immune infiltration (Supplementary Fig. 4A–C). Third,
by the use of parallel and independent expression data to match
cytolytic score, TCR/BCR reads, and characteristic expression
signatures with methylCIBERSORT estimates (Supplementary
Figs. 6E, 7, and 8). Fourth, by the use of parallel histopathology/
IHC-based estimates of infiltration in 30 MB/MRT samples and
61 pHGG (Figs. 1e, f and 5e).
Finally, our results and the immune clusters we have begun to
develop here indicate important differences in TIME across
pediatric brain tumor types; we summarize the key findings in
Fig. 6. We can show that our immune clusters are clearly related
to the expression of conventional immune targets such as PDL1
in MB and ATRT, and in a broad sense indicate which immune
subgroups are “hot” or “cold.” The immune clusters identified
break down, broadly speaking, into the monocyte dominated (i.e.,
panCNSIC3 and pHGGIC1/2), the balanced, or CD4+ T-type (i.e.,
panCNSIC1, MBIC2/3, and MRTIC2) and the CD8+ T-type (i.e.,
panCNSIC2, MBIC1/4, and pHGGIC3). With such information, one
may in future begin to match individuals or groups of individual
TIMEs to immunotherapy responses or lack thereof. Even in the
most simplistic terms, it seems to follow that an a priori paucity
of infiltrating cytotoxic T-lymphocytes and the lack of a sup-
portive TIME may be unconducive to immune checkpoint
blockade as a therapeutic strategy, but instead may be amenable
to approaches that alter the TIME or genetically redirect T-cell
immunity.
In conclusion, this analysis gives first indications of the
potential future therapeutic and prognostic possibilities of
immuno-methylomic profiling as an adjunct to methylation/
Fig. 5 Deconvolution analysis of pHGG immune infiltration by subgroup. a Barplots of the estimated median infiltration of specific cell types as a
proportion of all non-cancer cell types (range scaled from 0 to 1) in 401 pHGG (pediatric High-Grade Glioma) by subgroup (as per Mackay et al.38). b t-
SNE plot representing the methylation profiles of 401 pHGG. The colors of dots in the central panel map to subgroup. Background shading represents the
2D spatial density estimation of the amount of tumor-infiltrating lymphocytes (TILs); red shading equals relatively greater than average infiltration and blue
less than average. Exploded side panels represent enlarged areas of interest wherein both dot color and background shading represent the relative amount
of the particular immune cell infiltration denoted. Red denotes relatively greater than average infiltration and blue less than average. c Kaplan–Meier plot
showing significant difference in overall survival in WT-A (log-rank, p < 0.001, n= 80), WT-C (log-rank, p= 0.045, n= 80), and G34 subgroups (log-rank,
p= 0.011, n= 42) by low (<median) or high (>median) levels of B-cell and NK infiltration. d Boxplot showing the proportion of monocytes and CD4T cells
in pHGG by the presence/absence of a MAPK mutation (Wilcoxon= 3614, p < 0.001, n= 143). Box represents interquartile range, center line represents
median, whiskers represent range of minima and maxima excluding outliers. e Boxplot showing TIL proportion as estimated by methylCIBERSORT for a
subset of pHGG samples for which histopathology-based estimates of lymphocyte infiltration were available (F= 7.8, p= 0.007, n= 61). Patients are
categorized as per Rutledge et al.47. Box represents interquartile range, center line represents median, whiskers represent range of minima and maxima.
Estimates of TILs were significantly greater in patients classified as Categories 1 (present) or 2 (abundant) than Category 0 (absent).
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expression-based sub-classification. A future, in-depth, high-
resolution approach incorporating spatial information is now
required and we suggest that in silico deconvolution approaches
may ultimately be used to triage and to inform selection of
immunotherapy approaches in pediatric CNS tumor patients.
Methods
Construction of signature matrix for deconvolution. Raw 450K/850K Illumina
Methylation array (.idat) files were obtained from the following sources and
included reference samples additional to those used by Chakravarthy et al.40.
CD8+ T-cells, CD14+ monocytes, CD19+ B-cells, and CD56+ NK profiles were
obtained from the FlowSorted.Blood.450k & FlowSorted.CordBloodNorway.450k
packages (R/Bioconductor); CD4+ T-cells and CD4+ Treg profiles were obtained
from Gene Expression Omnibus (GEO) Dataset GSE49667; neuron and glial
profiles from GSE50798; and endothelial profiles from GSE82234. One hundred
and sixty-nine profiles distinguished between 12 broad cell types, namely effector
T-cells (CD4+ CD45RA+ CD45RO− CD25−), regulatory T-cells (CD4+
CD45RA+ CD45RO− CD25+ FOXP3+), CD8 T-cells (CD8+), B-cells (CD19+),
NK cells (CD56+), eosinophils (Singlec-8+ CCR3+), neutrophils (CD3- CD16+),
monocytes (CD14+), endothelial cells (Huvec), glial cells (NeuN−), neuronal cells
(NeuN+), and cancer (for full details see Supplementary Table 1). The signature
matrix construction method and the majority of reference profiles were broadly as
per Chakravarthy et al.40 with minor methodological changes. Specifically, the
custom limma-based package (MethylCIBERSORT) developed by Chakravarthy
et al.40 was used to fit linear models for each pairwise comparison between cell
types with the following change made to the internal R function “MethylCI-
BERSORT::FeatureSelect.V4” for the purpose of this analysis with respect to the
parameter “MaxDMPs.” Previously, the function selected n=MaxDMPs
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Fig. 6 Summary of immune clusters and associated characteristics. a Schematic representation of the broadly defining features of immune clusters
described in our analysis and a summary of select findings. Icons show the relative frequency of immune cluster membership and the distribution of
particular subgroups. Color shading represents broad similarities between the panCNS immune clusters and the more refined tumor type-specific immune
clusters. Yellow broadly denotes a pattern of relatively increased CD4+ T infiltration with low–moderate levels of infiltration of other cell types and a lack
of CD8+ T, a “balanced/CD4+ type.” Red broadly denotes a pattern of relatively increased CD8+ T infiltration, a “CD8+ type,” and blue broadly denotes a
pattern of relatively increased infiltration of monocytes, a “monocytic type”. MRTIC3 is not shown here, as it represents only a small number of patients.
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meaningful probes from the pairwise comparisons using a descending rank ordered
by beta–delta, selecting only from the positively enriched probes. We amended the
function to select MaxDMPs/2 unique probes from the positive- and negative-
ranked beta–delta lists, respectively. This corrected a bias in the resulting signature
matrix where the order of the pairwise comparisons had an effect on the resulting
probes selected.
.idat files were processed, QC (Quality Control) checked, and normalized by
single-sample Noob using the minfi package (R/Bioconductor). The custom
limma-based function as described by Chakravarthy et al.40 was used to fit linear
models performing a pairwise comparison between each of the cell types. A
maximum of 200 top features per pairwise comparison were selected, restricting to
probes showing a median β-value difference of 0.2 and false discovery rate of 0.01.
β-Values were scaled to between 0 and 100, and probe means per cell type
calculated to form a signature matrix compatible with CIBERSORT. The final
signature matrix was selected from several matrices following a parameter search
with benchmarking for deconvolution performance. Multiple cut-off parameters
for the signature matrix were tested. Each reasonable combination of median β-
value delta (0.2 and 0.3) and number of CpGs per pairwise comparison (100, 200,
300, 400, and 500) were tested using the known flow cytometry dataset
(GSE112618) and mean methylCIBERSORT correlation, root-mean-square error
scores, and the proportion of results not attributed to the six input populations
were used as a measure of signature performance (Supplementary Fig. 1).
Post-feature correction and QC checks. Variation in β-values in the CpGs
identified by feature selection was noted for cell line profiles comprising the
“Cancer” fraction. To prevent the estimation being confounded by cell line
variability, post-selection filtering was applied on the signature matrix. Probes,
where an average β-value difference between MB and MRT cell lines exceeded 0.1,
with an SD exceeding 0.15 in MB cell lines, were removed from the final signature
matrix. In addition, SD and variance were calculated probewise for all signature
probes using the panCNS dataset. A per tumor type average SD threshold of 0.005
was applied to check for extremely low variation or invariant probes, which may be
confounding or unlikely to represent real-world CNS tumor infiltration. Two sets
of invariant probes were identified using this threshold; however, the first was
clearly associated with a common neuronal, glial, or endothelial signature and the
second was associated with a common cancer or immune cell-type signature. We
therefore elected to retain these, as they were nevertheless clearly related to cell type
and likely less variable as a result of relatively small levels of infiltration particularly
of the neuronal, glial, and endothelial cell types. We did not identify any further
probes, which were below the SD threshold. Furthermore, the mean and SD of β-
values (for CpGs within the signature matrix) for each cell type and CNS tumor
type were examined (see Supplementary Fig. 2A). The pattern of large β-value
variations within the reference cell types and small variations between the CNS
tumor types is consistent with these CpGs correctly representing a minor infil-
trating population within a uniform majority cancer cell population.
methylCIBERSORT. Input methylation matrices were created by processing raw.
idat files as per above. Data were sourced from published GEO and ArrayExpress
datasets and 79 previously unpublished MRT methylation profiles from
SMARCB1-negative patients (see Supplementary Table 2 and Supplementary
Data 2). CIBERSORT was run in relative mode using the provided R script (https://
cibersort.stanford.edu) using 1000 permutations without quantile normalization.
Validation and benchmarking of signature matrix. The signature matrix was
inspected to verify that each cell type was accounted for by specific hypo/hyper-
methylated CpGs and not unduly compromised by batch effects. Likewise, t-SNE
(package Rtsne, R/Bioconductor) was used to visualize the cell-type specificity of
the signature matrix. The mean and SD of signature matrix CpGs were inspected in
each of the 80 CNS tumor methylation types represented in dataset GSE109381 to
identify possible outlier or confounding effects between immune-cell-type-specific
CpGs and tumor cell types (see above).
Deconvolution performance was benchmarked against 18 gold standards, i.e.,
6× methylation profiles of PBMC mixtures with known flow cytometry and 12×
mixtures of reference pure population DNA in known proportions (GSE112618).
Performance was also benchmarked against simulated mixtures generated to
contain known quantities of a given cell type. This was achieved by taking the
mean β-value of each pure cell reference and applying a random uniform
distribution such that each simulated mixture contained a fixed amount of a given
cell type (100 simulations for each) and a fixed 75% cancer cell signature derived
from relevant cancer cell reference lines (see Supplementary Table 1). Correlation
with methylCIBERSORT estimates was tested by the Spearman’s rank method.
meTIL score (an independent measure of T-lymphocyte infiltration based upon
methylation status of five CpGs—cg20792833, cg23642747, cg12069309, cg20425130,
and cg21554552—was calculated following the code provided in Jeschke et al.41.
Generation of synthetic mixtures for benchmarking signature performance. β-
Values used to derive the signature matrix were averaged to obtain a mean profile
for each signature matrix population. For 100 simulations per 12 signature
populations (1200 total simulated samples), set proportions for each population
were used while the other 11 were randomly calculated from a uniform distribution
function, such that the sum of proportions was equal to 1. To simulate a tumor
sample, the proportions were then scaled by 0.25 and a set proportion of 0.75 was
defined for the ‘Cancer’ population as modeled by cancer cell line profiles. These
proportions were used in a weighted mean to generate the final simulated mixture
profiles. methylCIBERSORT was run on these samples as in other analyses.
Signature to distinguish microglia from peripheral monocytes. Three expres-
sion signatures were adapted from Haage et al.45 to try to approximate the relative
contribution of microglia to the monocyte populations predicted by methylCI-
BERSORT. To define microglia, we used the following genes: ENSG00000181631
(P2RY13), ENSG00000169313 (P2RY12), ENSG00000171659 (GPR34), ENSG000
00142583 (SLC2A5), ENSG00000116774 (OLFML3), and ENSG00000183160
(TMEM119). To define peripheral macrophages, we used the following: ENSG
00000126218 (F10), ENSG00000132205 (EMILIN2), ENSG00000198734 (F5),
ENSG00000125730 (C3), ENSG00000119125 (GDA), ENSG00000188404 (SELL),
and ENSG00000257017 (HP). To define all monocytes of whichever type, we used
the following genes: (ENSG00000169896 (CD11B) and ENSG00000081237 (CD45).
Genes were originally selected by Haage et al.45, because their expression was high
and relatively equivalent within the target cell populations. We tried weighting
according to their average expression and standardizing to variation, and
attempted to quantify using ssGSEA/GSVA. Ultimately, each method differed little
from the averaged standardized expression of each of the genes and so for the sake
of simplicity this was used. A ratio of microglia to peripheral monocytes signatures
was used to approximate the contribution of microglia in 36 pHGG for which
parallel RNA-seq and methylation profiles were available. The signature scores
were each significantly correlated (p < 0.001) with the proportion of monocytes
estimated by methylCIBERSORT (see Supplementary Fig. 3).
Visualization and clinico-pathological associations. Visualizations were created
using the ggplot2, survminer packages (R/ Bioconductor). Relative cell proportions
were categorized as higher or lower than median for the dataset in question. Bilinear
density estimators were calculated from t-SNE coordinates using Rtsne, akima
(R/Bioconductor/CRAN). Associations with survival were assessed using Cox pro-
portional hazards and/or log-rank test. Patients were stratified according to whether
they had greater than or lower than median for a given infiltrating cell type. Dif-
ferences in cell proportions by subgroup or clinico-pathological criteria were tested
by KW test with post hoc testing (Dunn’s test). Analysis of variance (F) or Wilcoxon
test (W) was used where appropriate and where indicated. Associations between
immune subgroup and categorical, i.e., clinico-pathological, variables were tested by
χ2-test. All correlations and associated significance tests used Spearman’s rank and all
p-values were adjusted for multiple hypothesis testing using Benjamini–Hochberg.
Consensus clustering of immune estimates was by k-means using Consensu-
sClusterPlus (R/Bioconductor) testing range of k= 2 to k= 6. A support vector
machine classifier using e1071 (R/CRAN) was trained on immune clusters derived
from the panCNS analysis and tested on the MB, MRT, and pHGG cohorts.
MiXCR44 analysis was used to derive CDR3 sequence clonotypes. ssGSEA was
performed using gsva54(R/Bioconductor) using the GSE22886 gene sets from within
the C7 library of MSigDB. When visualizing the median proportion of estimated
non-cancer cells using a barplot in Figs. 2a, 3a, 4a, and 5a, the median estimated
proportion of each cell type except for “cancer” were plotted after scaling to the
maximum total value such that the bars give both an impression of the proportion of
the estimated cell types and also the total relative amounts of infiltrating cells.
Validation of predicted immune cell infiltration. An IHC panel using antibodies
for CD8 1 : 250 dilution (Ventana Medical Systems Confirm anti-CD8 SP57; cat-
alog number 790-4460) and CD20 1 : 200 dilution (Ventana Medical Systems
Confirm anti-CD20 L26; catalog number 760-2531) was applied to pre-mounted
slides using the fully automated Ventana BenchMark XT IHC system and standard
detection reagents ultraVIEW Universal DAB Detection kit (Ventana Medical
Systems; catalog number 760-500), incorporating antigen retrieval with Ventana
ultra cell conditioning 1 and a hematoxylin counterstain (Ventana Medical Sys-
tems: catalog number 950-224). Leica Aperio membrane v9 analysis algorithm
(Aperio ImageScope V12.4.0.7018) was applied to the stained slides.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Reference cell profiles are available as part of the packages methylCIBERSORT, FlowSorted.
Blood.450k & FlowSorted.CordBloodNorway.450k (R/Bioconductor), and GEO datasets
GSE82234, GSE50798, GSE49667, GSE112618, GSE110554, and GSE88824. For the tumor
cohorts: GEO datasets GSE70460, GSE109381, GSE60274, GSE93646, GSE85212, and
GSE130051; ArrayExpress datasets E-MTAB-5528, E-MTAB-5552, and E-MTAB-6708.
PedCBioPortal datasets phgg_herby and phgg_jones_meta_2017. Full details are given in
“Methods,” Supplementary Information, and Supplementary Data. All remaining relevant
data are available in the article, Supplementary Information, or from the corresponding
author upon reasonable request.
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Code availability
Code used to generate the signature matrix as well as the resulting signature matrix have
been deposited in Github [https://github.com/dannlbol/mcibersort_scripts].
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